155 related articles for article (PubMed ID: 37708925)
21. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
Bowering K; Case C; Harvey J; Reeves M; Sampson M; Strzinek R; Bretler DM; Bang RB; Bode BW
Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
[TBL] [Abstract][Full Text] [Related]
22. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.
Thalange N; Deeb L; Iotova V; Kawamura T; Klingensmith G; Philotheou A; Silverstein J; Tumini S; Ocampo Francisco AM; Kinduryte O; Danne T
Pediatr Diabetes; 2015 May; 16(3):164-76. PubMed ID: 25683037
[TBL] [Abstract][Full Text] [Related]
23. Insulin delivery systems combined with microneedle technology.
Jin X; Zhu DD; Chen BZ; Ashfaq M; Guo XD
Adv Drug Deliv Rev; 2018 Mar; 127():119-137. PubMed ID: 29604374
[TBL] [Abstract][Full Text] [Related]
24. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.
Hirsch IB; Bode B; Courreges JP; Dykiel P; Franek E; Hermansen K; King A; Mersebach H; Davies M
Diabetes Care; 2012 Nov; 35(11):2174-81. PubMed ID: 22933438
[TBL] [Abstract][Full Text] [Related]
25. PVA-based bulk microneedles capable of high insulin loading and pH-triggered degradation for multi-responsive and sustained hypoglycemic therapy.
Ma Y; Wang W; He M; Liu Y; Li C; Zhong Y; Bu Q; Huang D; Qian H; Chen W
Biomater Sci; 2024 Jan; 12(2):507-517. PubMed ID: 38088652
[TBL] [Abstract][Full Text] [Related]
26. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes.
Heise T; Pieber TR; Danne T; Erichsen L; Haahr H
Clin Pharmacokinet; 2017 May; 56(5):551-559. PubMed ID: 28205039
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of fast-acting insulin aspart versus insulin aspart in children and adolescents with type 1 diabetes from Japan.
Kawamura T; Kikuchi T; Horio H; Rathor N; Ekelund M
Endocr J; 2021 Apr; 68(4):409-420. PubMed ID: 33518615
[TBL] [Abstract][Full Text] [Related]
28. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart.
Basu A; Pieber TR; Hansen AK; Sach-Friedl S; Erichsen L; Basu R; Haahr H
Diabetes Obes Metab; 2018 Jul; 20(7):1615-1622. PubMed ID: 29493118
[TBL] [Abstract][Full Text] [Related]
29. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
Christiansen JS; Niskanen L; Rasmussen S; Johansen T; Fulcher G
J Diabetes; 2016 Sep; 8(5):720-8. PubMed ID: 26612062
[TBL] [Abstract][Full Text] [Related]
30. Laser-engineered dissolving microneedle arrays for transdermal macromolecular drug delivery.
Migalska K; Morrow DI; Garland MJ; Thakur R; Woolfson AD; Donnelly RF
Pharm Res; 2011 Aug; 28(8):1919-30. PubMed ID: 21437789
[TBL] [Abstract][Full Text] [Related]
31. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
Klonoff DC; Evans ML; Lane W; Kempe HP; Renard E; DeVries JH; Graungaard T; Hyseni A; Gondolf T; Battelino T
Diabetes Obes Metab; 2019 Apr; 21(4):961-967. PubMed ID: 30537180
[TBL] [Abstract][Full Text] [Related]
32. Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes.
Bebakar WM; Chaykin L; Hersløv ML; Rasmussen S
Diabetes Ther; 2017 Feb; 8(1):197-205. PubMed ID: 27853981
[TBL] [Abstract][Full Text] [Related]
33. Thermosensitive hydrogel microneedles for controlled transdermal drug delivery.
Li JY; Feng YH; He YT; Hu LF; Liang L; Zhao ZQ; Chen BZ; Guo XD
Acta Biomater; 2022 Nov; 153():308-319. PubMed ID: 36055607
[TBL] [Abstract][Full Text] [Related]
34. A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.
Haahr H; Fita EG; Heise T
Clin Pharmacokinet; 2017 Apr; 56(4):339-354. PubMed ID: 27696221
[TBL] [Abstract][Full Text] [Related]
35. IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status.
Christiansen JS; Home P; Kumar A
Expert Rev Endocrinol Metab; 2016 Mar; 11(2):103-111. PubMed ID: 30058868
[TBL] [Abstract][Full Text] [Related]
36. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.
Fath M; Danne T; Biester T; Erichsen L; Kordonouri O; Haahr H
Pediatr Diabetes; 2017 Dec; 18(8):903-910. PubMed ID: 28165180
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
[TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy and safety of insulin aspart compared with regular human insulin in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis.
Wojciechowski P; Niemczyk-Szechowska P; Olewińska E; Jaros P; Mierzejewska B; Skarżyńska-Duk J; Małecki MT; Ryś P
Pol Arch Med Wewn; 2015; 125(3):141-51. PubMed ID: 25644227
[TBL] [Abstract][Full Text] [Related]
39. Rapidly dissolvable microneedle patches for transdermal delivery of exenatide.
Zhu Z; Luo H; Lu W; Luan H; Wu Y; Luo J; Wang Y; Pi J; Lim CY; Wang H
Pharm Res; 2014 Dec; 31(12):3348-60. PubMed ID: 24867426
[TBL] [Abstract][Full Text] [Related]
40. Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients.
Hirose T; Awata T; Yamamoto Y; Hemmingsen MP
Expert Opin Biol Ther; 2018 Jan; 18(1):77-85. PubMed ID: 29017373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
